The Vaccine Adjuvants Market by Type of Vaccine Adjuvant (Aluminum Salts, Oil-based Emulsions, Bacterial Compounds, Lipids, Nucleic Acids, and Others), Route of Administration (Intramuscular, Subcutaneous, Oral, Intravenous and Others), Target Therapeutic Area (Infectious Diseases, Oncological Disorders, and Others) and Key Geographies (North America, Europe, Asia-Pacific, Latin America, MENA, and RoW): Industry Trends and Global Forecasts, 2022-2035

  • Lowest Price Guaranteed From USD 5,899

  • Published
    May 2022

  • Pages
    268

  • View Count
    686

Example Insights

Vaccine-Adjuvants-Market-Context-thumb Vaccine-Adjuvants-Market-List-of-Vaccine-Adjuvant-Developers-thumb Vaccine-Adjuvants-Market-Distribution-by-Phase-of-Development-thumb
Vaccine-Adjuvants-Market-Competitiveness-Analysis-thumb Vaccine-Adjuvants-Market-Clinical-Trial-Analysis-thumb Vaccine-Adjuvants-Market-Patent-Analysis-thumb
Vaccine-Adjuvants-Market-Potential-Strategic-Partners-thumb Vaccine-Adjuvants-Market-Partnerships-and-Collaborations-thumb Vaccine-Adjuvants-Market-Funding-and-Investments-thumb
Vaccine-Adjuvants-Market-Distribution-by-Geographical-Region-thumb    

Overview

As per recent estimates (reported in May 2022), more than 11.6 billion doses of COVID-19 vaccines have been administered across 184 countries; this value roughly translates to 20.9 million doses per day. Vaccines have enabled the prevention of more than 37 million deaths due to various disease indications, such as cholera, diphtheria, influenza, tetanus, whooping cough and measles, between 2000 to 2019. Given the rate at which the global population is growing and taking into consideration the prevalent (such as the COVID-19 pandemic) and anticipated future trends, the demand for vaccines is likely to increase significantly. According to experts, the global vaccines market is anticipated to generate revenues worth USD 100 billion by 2025. In this regard, significant strides have been made to develop safe and effective, next generation vaccine candidates, such as sub-unit vaccines, recombinant vaccines, conjugate vaccines and DNA vaccines. However, such vaccines employ purified non-living vaccine antigens (unlike their counterparts, live attenuated and inactivated vaccines) and are, most often, less immunogenic and require an additional aid to increase their immunogenicity against the target antigens. As a result, a variety of vaccine adjuvants (substances with the innate potential to augment an immune response), such as AS04 (Cervarix®), MF59 (Fluad®), AS01B (Shingrix®) and CpG 1018 (Heplisav-B®), have been discovered and are now available for the development of more effective and versatile vaccine formulations.  

Presently, an increasing number of vaccines under development are incorporating vaccine adjuvants owing to various advantages offered by such agents, including improved adaptive response to a vaccine, guiding the type of adaptive response to produce the most effective forms of immunity for each specific pathogen and facilitation of the use of smaller doses of antigen. Further, majority of the adjuvants used in human vaccines enhance humoral immunity; however, several novel adjuvants in clinical or preclinical development are focused on enhancing specific types of T-cell responses to generate multifaceted immune responses required for complex indications, such as malaria and HIV-AIDS. Currently, more than 70 companies and academic / research institutes are engaged in the development of various types of vaccine adjuvants. It is worth highlighting that capital investments worth over USD 5.5 billion have been made by various private and public sector investors during the last five years to fund the product development activity in this domain. In addition, there have been several recently reported instances of collaborations between industry / academic stakeholders to advance the development of various vaccine adjuvants. Driven by the increasing demand for safe and effective vaccines, ongoing pace of innovation in this field and financial support from the investors, the vaccine adjuvants market is likely to witness substantial growth in the mid to long-term.

Scope of the Report

The ‘Vaccine Adjuvants Market – Distribution by Type of Vaccine Adjuvant (Aluminum Salts, Oil-based Emulsions, Bacterial Compounds, Lipids, Nucleic Acids and Others), Route of Administration (Intramuscular, Subcutaneous, Oral, Intravenous and Others), Target Therapeutic Area (Infectious Diseases, Oncological Disorders and Others) and Key Geographies (North America, Europe, Asia-Pacific, Latin America, MENA and RoW): Industry Trends and Global Forecasts, 2022-2035’ report features an extensive study of the current market landscape and future potential of the vaccine adjuvant market. The study features an in-depth analysis, highlighting the capabilities of vaccine adjuvant developers. Amongst other elements, the report features:

  • A detailed overview of the overall landscape of vaccine adjuvant developers, along with information on several relevant parameters, such as their year of establishment, company size (in terms of employee count), location of headquarters (North America, Europe, Asia-Pacific and rest of the world), type of vaccine adjuvant (based on composition (aluminum salts, oil-based emulsions, bacterial compounds, lipids, nucleic acids, and others), based on chemical structure (inorganic adjuvants and organic adjuvants), based on function (humoral immunity activator, cell-mediated immunity activator and others)), phase of development (preclinical, clinical, commercial, and undisclosed), type of product (combinational adjuvants and individual adjuvants), type of molecular target (toll-like receptors, CD4 + T cells, and others), route of administration (intramuscular, subcutaneous, intranasal, intravenous, intraperitoneal, intradermal, oral and sublingual), target therapeutic area (infectious diseases, oncological disorders, immunological disorders, and dermatological disorders), type of compatible vaccine (Sub-unit, Inactivated, DNA / RNA, conjugate, live-attenuated, toxoid and others) and application area (human vaccine adjuvants, veterinary vaccine adjuvants and research vaccine adjuvants).
  • An insightful competitiveness analysis of vaccine adjuvant developers, based on supplier power (in terms of years of experience), company competitiveness (type of vaccine adjuvant (based on composition, chemical structure, function), type of product, type of molecular target, phase of development, type of compatible vaccine, route of administration, type of therapeutic area and application area) and number of vaccine adjuvants developed.
  • Elaborate profiles of prominent players (shortlisted based on a proprietary criterion) engaged in this domain. Each profile features a brief overview of the company (including information on year of establishment, number of employees, location of headquarters and key executives), financial information (if available), details related to vaccine adjuvant portfolio, recent developments, and an informed future outlook.
  • A detailed analysis of completed, ongoing and planned clinical studies, based on several relevant parameters, such as trial registration year, enrolled patient population, trial recruitment status, trial phase, target patient segment, type of sponsor / collaborator, most active players and regional distribution of trials.
  • An in-depth analysis of patents related to vaccine adjuvants, filed / granted since 2017, based on several relevant parameters, such as patent type, application year, publication year, geographical distribution, Cooperative Patent Classification (CPC) symbols, emerging focus areas, type of applicant, leading players (on the basis of number of patents) and patent benchmarking. In addition, it features a patent valuation analysis which evaluates the qualitative and quantitative aspects of the patents.
  • An in-depth analysis of around 50 vaccine developers that are likely to partner with vaccine adjuvant developers, based on several relevant parameters, such as developer strength (on the basis of company size and its experience), pipeline strength and maturity (on the basis of number of vaccines in pipeline and their stage of development) and type of vaccine. 
  • An analysis of recent partnerships inked between stakeholders engaged in this domain, during the period 2018-2022 (till February), covering acquisitions, commercialization agreements, joint ventures, licensing agreements, manufacturing agreements, material transfer agreements, mergers, product development agreements, research development agreements, service agreements, service alliances and supply agreements. Further, the partnership activity in this domain has been analyzed based on various parameters, such as year of partnership, type of partnership, type of vaccine adjuvant, type of product and most active players (on the basis of number of partnerships). It also highlights the regional distribution of the partnership activity in this market.
  • A detailed analysis of various investments received by players engaged in this domain, during the period 2018-2022 (till February), based on several relevant parameters, such as year of investment, number of funding instances, amount invested, type of funding (grant, seed, venture capital, initial public offering, secondary offering, other equity, and debt) and type of investor, along with information on the most active players (in terms of number of funding instances and amount raised), most active investors (in terms  of number of funding instances) and geographical distribution (in terms of number of funding instances and amount invested).
  • A case study presenting the USFDA approved vaccines, along with the information on their year of approval, type of vaccine, type of vaccine adjuvant and target therapeutic area.

One of the key objectives of the report was to evaluate the current opportunity and future potential associated with the vaccine adjuvant market, over the coming 13 years. We have provided informed estimates of the likely evolution of the market in the short to mid-term and long term, for the period 2022-2035. Our year-wise projections of the current and future opportunity have further been segmented based on relevant parameters, such as [A] type of vaccine adjuvant (aluminum salts, oil-based emulsions, bacterial compounds, lipids, nucleic acids, and others), [B] route of administration (intramuscular, subcutaneous, oral, intravenous, and others), [C] target therapeutic area (infectious diseases, oncological disorders, and others), and [D] key geographical regions (North America, Europe, Asia-Pacific, Latin America, MENA and rest of the world). To account for future uncertainties in the market and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

The opinions and insights presented in the report were also influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following individuals:

  • Bernard Verrier (Co-founder, Adjuvatis)
  • Johanna Holldack (Chief Executive Officer, Kupando)
  • Cindy Tsang (Director of Business Development, Pacific GeneTech

Key Questions Answered

  • Who are the leading players engaged in the vaccine adjuvants domain?
  • Which global regions are considered as key hubs for vaccine adjuvant research and development?
  • What is the relative competitiveness of different vaccine adjuvant developers?
  • Which type of vaccines are suitable for vaccine adjuvants?
  • Which type of partnership model is most commonly adopted by industry stakeholders?
  • Who are the key investors in this domain? 
  • How is the current and future market opportunity likely to be distributed across key market segments?

Contents

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured during our research. It offers a high-level view on the likely evolution of the vaccine adjuvants market in the short to mid-term, and long term.

Chapter 3 provides a general overview of vaccines and vaccine adjuvants, including information on importance / need for vaccine adjuvants in the pharmaceutical industry. Further, it contains details on mechanism of action and classification of different vaccine adjuvants. The chapter concludes with a discussion on the advantages of vaccine adjuvants and factors which would lead to projected growth in the coming years.

Chapter 4 features a detailed review of the current market landscape of around 70 companies developing vaccine adjuvant. Additionally, it features an in-depth analysis of vaccine adjuvant developers, based on a number of relevant parameters, such as their year of establishment, company size (in terms of employee count), location of headquarters (North America, Europe, Asia-Pacific and rest of the world), type of vaccine adjuvant (based on composition (aluminum salts, oil-based emulsions, bacterial compounds, lipids, nucleic acids, and others), based on chemical structure (inorganic adjuvants and organic adjuvants), based on function (humoral immunity activator, cell-mediated immunity activator and others)), phase of development (preclinical, clinical, commercial, and undisclosed), type of product (combinational adjuvants and individual adjuvants), type of molecular target (toll-like receptors, CD4 + T cells, and others), route of administration (intramuscular, subcutaneous, intranasal, intravenous, intraperitoneal, intradermal, oral and sublingual), target therapeutic area (infectious diseases, oncological disorders, immunological disorders, and dermatological disorders), type of compatible vaccine (Sub-unit, Inactivated, DNA / RNA, conjugate, live-attenuated, toxoid and others) and application area (human vaccine adjuvants, veterinary vaccine adjuvants and research vaccine adjuvants).

Chapter 5 presents an insightful competitiveness analysis of the vaccine adjuvant developers, located in North America, Europe, and Asia-Pacific and rest of the world. The companies are further segmented based on their employee count, into three categories, namely small (1-50 employees), mid-sized (51-500 employees) and large (>500 employees) across these geographies. The analysis compares the vaccine adjuvant developers, based on supplier power (in terms of years of experience), company competitiveness (type of vaccine adjuvant (based on composition, chemical structure, function), type of product, type of molecular target, phase of development, type of compatible vaccine, route of administration, type of therapeutic area and application area) and number of vaccine adjuvants developed.

Chapter 6 consist of detailed profiles of the prominent players (shortlisted based on a proprietary criterion) that are engaged in development of vaccine adjuvants in North America. Each profile features a brief overview of the company (including information on year of establishment, number of employees, location of headquarters and key executives), financial information (if available), details related to vaccine adjuvant portfolio, recent developments, and an informed future outlook.

Chapter 7 consist of detailed profiles of the prominent players (shortlisted based on a proprietary criterion) that are engaged in development of vaccine adjuvants in Europe. Each profile features a brief overview of the company (including information on year of establishment, number of employees, location of headquarters and key executives), financial information (if available), details related to vaccine adjuvant portfolio, recent developments, and an informed future outlook.

Chapter 8 consist of detailed profiles of the prominent players (shortlisted based on a proprietary criterion) that are engaged in development of vaccine adjuvants in Asia-Pacific and Rest of the World. Each profile features a brief overview of the company (including information on year of establishment, number of employees, location of headquarters and key executives), financial information (if available), details related to vaccine adjuvant portfolio, recent developments, and an informed future outlook.

Chapter 9 provides a detailed analysis of completed, ongoing and planned clinical studies, based on several relevant parameters, such as registration year, enrolled patient population, trial recruitment status, trial phase, target patient segment, type of sponsor / collaborator, most active players, and regional distribution of trials.

Chapter 10 consists of an analysis of patents related to vaccine adjuvants, filed / granted since 2017, based on several relevant parameters, such as patent type, application year, publication year, geographical distribution, Cooperative Patent Classification (CPC) symbols, emerging focus areas, type of applicant, leading players (on the basis of number of patents), and patent benchmarking. In addition, it features a patent valuation analysis which evaluates the qualitative and quantitative aspects of the patents.

Chapter 11 present an in-depth analysis of over 50 vaccine developers that are likely to partner with vaccine adjuvant developers, based on several relevant parameters, such as developer strength (on the basis of company size and its experience), pipeline strength and maturity (on the basis of number of vaccines in pipeline and their stage of development) and type of vaccines.

Chapter 12 features an analysis of the various collaborations and partnerships that have been inked by stakeholders engaged in this domain, during the period 2018-2022. It includes a brief description of the partnership models (including acquisitions, commercialization agreements, joint ventures, licensing agreements, manufacturing agreements, material transfer agreements, mergers, product development agreements, research development agreements, service agreement, service alliance and supply agreements) adopted by stakeholders in this domain. Further, the partnership activity in this domain has been analyzed based on various parameters, such as year of partnership, type of partnership, type of vaccine adjuvant, type of product and most active players (on the basis of number of partnerships). Further, the chapter includes a world map representation of all the deals inked in this field in the period 2018-2022, highlighting both intercontinental and intracontinental partnership activity.

Chapter 13 presents details on various investments received by various players engaged in vaccine adjuvant domain. Based on several relevant parameters, such as year of investment, number of funding instances, amount invested, type of funding (grant, seed, venture capital, initial public offering, secondary offering, other equity, and debt) and type of investor, along with information on the most active players (in terms of number of funding instances and amount raised), most active investors (in terms  of number of funding instances) and geographical distribution (in terms of number of funding instances and amount invested).

Chapter 14 presents an insightful market forecast analysis, highlighting the likely growth of the vaccine adjuvant market till the year 2035. In order to provide details on the future opportunity, our projections have been segmented on the basis of [A] type of vaccine adjuvant (aluminum salts, oil-based emulsions, bacterial compounds, lipids, nucleic acids, and others), [B] route of administration (intramuscular, subcutaneous, oral, intravenous, and others), [C] target therapeutic area (infectious diseases, oncological disorders, and others), [D] key geographical regions (North America, Europe, Asia-Pacific, Latin America, MENA and RoW).

Chapter 15 presents case study presenting the USFDA approved vaccines, along with information on their year of approval, type of vaccine, type of vaccine adjuvant and target therapeutic area.

Chapter 16 summarizes the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 17 provides the transcripts of the interviews conducted with representatives from renowned organizations that are engaged in developing vaccine adjuvants. The chapter contains the details of our conversation with Bernard Verrier (Co-founder, Adjuvatis), Johanna Holldack (Chief Executive Officer, Kupando) and Cindy Tsang (Director of Business Development, Pacific GeneTech).

Chapter 18 is an appendix, that provides tabulated data and numbers for all the figures included in the report.

Chapter 19 is an appendix that provides the list of companies and organizations that have been mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY
2.1. Chapter Overview

3. INTRODUCTION
3.1. Chapter Overview
3.2. Vaccines
3.3. An Overview of Vaccine Adjuvants
3.3.1. Historical Evolution
3.3.2. Mechanism of Action

3.3.3. Classification of Vaccine Adjuvants
3.3.3.1. Based on Composition
3.3.3.2. Based on Chemical Structure
3.3.3.3. Based on Function
3.3.3.4. Based on Molecular Targets

3.3.4. Advantages Offered by Vaccine Adjuvants
3.4. Concluding Remarks

4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Vaccine Adjuvants Developers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Type of Vaccine Adjuvants based on Composition
4.2.5. Analysis by Type of Vaccine Adjuvants based on Chemical Structure
4.2.6. Analysis by Type of Vaccine Adjuvants based on Function
4.2.7. Analysis by Phase of Development
4.2.8. Analysis by Type of Product
4.2.9. Analysis by Type of Molecular Target
4.2.10. Analysis by Route of Administration
4.2.11. Analysis by Target Therapeutic Area
4.2.12. Analysis by Type of Compatible Vaccines
4.2.13. Analysis by Application Area
4.2.14. Most Active Players: Analysis by Number of Vaccine Adjuvants Developed

5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Assumptions and Key Parameters
5.3. Methodology
5.4. Vaccine Adjuvants Developers: Company Competitiveness Analysis
5.4.1. Company Competitiveness Analysis: Small Players
5.4.2. Company Competitiveness Analysis: Mid-Sized Players
5.4.3. Company Competitiveness Analysis: Large Players

6. COMPANY PROFILES: VACCINE ADJUVANT DEVELOPERS BASED IN NORTH AMERICA
6.1. Chapter Overview
6.2. Adjuvance Technologies
6.2.1. Company Overview
6.2.2. Vaccine Adjuvant Offerings
6.2.3. Recent Developments and Future Outlook

6.3. Avanti Polar Lipids
6.3.1. Company Overview
6.3.2. Vaccine Adjuvant Offerings
6.3.3. Recent Developments and Future Outlook

6.4. Blue Willow Biologics
6.4.1. Company Overview
6.4.2. Vaccine Adjuvant Offerings
6.4.3. Recent Developments and Future Outlook

6.5. Novavax
6.5.1. Company Overview
6.5.2. Vaccine Adjuvant Offerings
6.5.3. Recent Developments and Future Outlook

6.6. Phibro Animal Health
6.6.1. Company Overview
6.6.2. Vaccine Adjuvant Offerings
6.6.3. Recent Developments and Future Outlook

6.7. Vaxart
6.7.1. Company Overview
6.7.2. Vaccine Adjuvant Offerings
6.7.3. Recent Developments and Future Outlook

7. COMPANY PROFILES: VACCINE ADJUVANT DEVELOPERS BASED IN EUROPE
7.1. Chapter Overview
7.2. CureVac
7.2.1. Company Overview
7.2.2. Vaccine Adjuvant Offerings
7.2.3. Recent Developments and Future Outlook

7.3. eTheRNA immunotherapies
7.3.1. Company Overview
7.3.2. Vaccine Adjuvant Offerings
7.3.3. Recent Developments and Future Outlook

7.4. GSK
7.4.1. Company Overview
7.4.2. Vaccine Adjuvant Offerings
7.4.3. Recent Developments and Future Outlook

8. COMPANY PROFILES: VACCINE ADJUVANT DEVELOPERS BASED IN ASIA-PACIFIC
8.1. Chapter Overview
8.2. Advagene Biopharma
8.2.1. Company Overview
8.2.2. Vaccine Adjuvant Offerings
8.2.3. Recent Developments and Future Outlook

8.3. OBI Pharma
8.3.1. Company Overview
8.3.2. Vaccine Adjuvant Offerings
8.3.3. Recent Developments and Future Outlook

9. CLINICAL TRIAL ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Vaccine Adjuvants: Clinical Trial Analysis
9.3.1. Analysis by Trial Registration Year
9.3.2. Analysis by Trial Registration Year and Enrolled Patient Population
9.3.3. Analysis by Trial Recruitment Status
9.3.4. Analysis by Trial Registration Year and Trial Status
9.3.5. Analysis by Trial Phase
9.3.6. Analysis of Enrolled Patient Population by Trial Phase
9.3.7. Analysis by Target Patient Segment
9.3.8. Analysis by Type of Sponsor / Collaborator
9.3.9. Most Active Industry Players: Analysis by Number of Registered Trials
9.3.10. Most Active Non-Industry Players: Analysis by Number of Registered Trials
9.3.11. Analysis by Key Focus Areas (Word Cloud Representation)
9.3.12. Analysis of Trials by Geography
9.3.13. Analysis of Enrolled Patient Population by Geography

10. PATENT ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Vaccine Adjuvants: Patent Analysis
10.3.1. Analysis by Application Year
10.3.2. Analysis by Publication Year
10.3.3. Analysis by Geography
10.3.4. Analysis by CPC Symbols
10.3.5. Analysis by Emerging Focus Areas
10.3.6. Analysis by Type of Applicant
10.3.7. Leading Players: Analysis by Number of Patents

10.4. Vaccine Adjuvants: Patent Benchmarking
10.4.1. Analysis by Patent Characteristics

10.5. Vaccine Adjuvants: Patent Valuation
10.6. Leading Patents: Analysis by Number of Citations

11. LIKELY PARTNERS ANALYSIS
11.1. Chapter Overview
11.2. Scoring Criteria and Key Assumptions
11.3. Scope and Methodology

11.4. Potential Strategic Partners
11.4.1. Potential Strategic Partners in North America
11.4.1.1. Most Likely Partners in North America
11.4.1.2. Likely Partners in North America
11.4.1.3. Less Likely Partners in North America

11.4.2. Potential Strategic Partners in Europe
11.4.2.1. Most Likely Partners in Europe
11.4.2.2. Likely Partners in Europe
11.4.2.3. Less Likely Partners in Europe

11.4.3. Potential Strategic Partners in Asia Pacific
11.4.3.1. Most Likely Partners in Asia Pacific
11.4.3.2. Likely Partners in Asia Pacific
11.4.3.3. Less Likely Partners in Asia Pacific

12. PARTNERSHIPS AND COLLABORATIONS
12.1. Chapter Overview
12.2. Partnership Models
12.3. Vaccine Adjuvants: List of Partnerships and Collaborations
12.3.1. Analysis by Year of Partnership
12.3.2. Analysis by Type of Partnership
12.3.3. Analysis by Year and Type of Partnership
12.3.4. Analysis by Type of Vaccine Adjuvant
12.3.5. Analysis by Type of Product
12.3.6. Analysis by Type of Partner Company
12.3.7. Most Active Players: Analysis by Number of Partnerships
12.3.8. Analysis by Geography
12.3.8.1. Intercontinental and Intracontinental Deals
12.3.8.2. International and Local Deals

13. FUNDING AND INVESTMENT ANALYSIS
13.1. Chapter Overview
13.2. Types of Funding
13.3. Vaccine Adjuvants: Funding and Investments
13.3.1. Analysis of Funding Instances by Year
13.3.2. Analysis of Amount Invested by Year
13.3.3. Analysis by Type of Funding
13.3.4. Analysis of Amount Invested and Type of Funding
13.3.5. Analysis by Type of Investor
13.3.6. Analysis of Amount Invested by Type of Investor
13.3.7. Analysis by Type of Vaccine Adjuvant
13.3.8. Most Active Players: Analysis by Number of Funding Instances
13.3.9. Most Active Players: Analysis by Amount Invested
13.3.10. Most Active Investors: Analysis by Number of Funding Instances

13.3.11. Analysis of Amount Invested by Geography
13.3.11.1. Analysis by Region
13.3.11.2. Analysis by Country

14. MARKET FORECAST
14.1. Chapter Overview
14.2. Key Assumptions and Methodology

14.3. Global Vaccine Adjuvants Market, 2022-2035
14.3.1. Analysis by Type of Vaccine Adjuvants
14.3.1.1. Vaccine Adjuvants Market for Aluminum Salts, 2022-2035
14.3.1.2. Vaccine Adjuvants Market for Oil-based Emulsions, 2022-2035
14.3.1.3. Vaccine Adjuvants Market for Lipids, 2022-2035
14.3.1.4. Vaccine Adjuvants Market for Bacterial Compounds, 2022-2035
14.3.1.5. Vaccine Adjuvants Market for Nucleic Acids, 2022-2035
14.3.1.6. Vaccine Adjuvants Market for Other Adjuvants, 2022-2035

14.3.2. Analysis by Route of Administration
14.3.2.1. Vaccine Adjuvants Market for Intramuscular Route, 2022-2035
14.3.2.2. Vaccine Adjuvants Market for Subcutaneous Route, 2022-2035
14.3.2.3. Vaccine Adjuvants Market for Oral Route, 2022-2035
14.3.2.4. Vaccine Adjuvants Market for Intravenous Route, 2022-2035
14.3.2.5. Vaccine Adjuvants Market for Other Route, 2022-2035

14.3.3. Analysis by Target Therapeutic Area
14.3.3.1. Vaccine Adjuvants Market for Infectious Diseases, 2022-2035
14.3.3.2. Vaccine Adjuvants Market for Oncological Disorders, 2022-2035
14.3.3.3. Vaccine Adjuvants Market for Other Disorders, 2022-2035

14.3.4. Analysis by Geography
14.3.4.1. Vaccine Adjuvants Market in North America, 2022-2035
14.3.4.2. Vaccine Adjuvants Market in Europe, 2022-2035
14.3.4.3. Vaccine Adjuvants Market in Asia-Pacific, 2022-2035
14.3.4.4. Vaccine Adjuvants Market in MENA, 2022-2035
14.3.4.5. Vaccine Adjuvants Market in Latin America, 2022-2035
14.3.4.6. Vaccine Adjuvants Market in Rest of the World, 2022-2035

15. CASE STUDY: USFDA APPROVED ADJUVANTED VACCINES
15.1. Chapter Overview
15.2. List of FDA Approved Vaccines
15.2.1. Analysis by Year of Approval
15.2.2. Analysis by Number of Adjuvanted Vaccines
15.2.3. Analysis by Type of Vaccine
15.2.4. Analysis by Type of Adjuvant
15.2.5. Analysis by Type of Vaccine and Type of Adjuvant
15.2.6. Analysis by Target Therapeutic Area

16. CONCLUSION

17. EXECUTIVE INSIGHTS
17.1. Chapter Overview
17.2. Adjuvatis
17.2.1. Company Snapshot
17.2.2. Interview Transcript: Bernard Verrier (Co-founder, Scientific Referent)

17.3. Kupando
17.3.1. Company Snapshot
17.3.2. Interview Transcript: Johanna Holldack (Chief Executive Officer)

17.4. Pacific GeneTech
17.4.1. Company Snapshot
17.4.2. Interview Transcript: Cindy Tsang (Director of Business Development)

18. APPENDIX I: TABULATED DATA

19. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 2.1 Executive Summary: Overall Market Landscape
Figure 2.2 Executive Summary: Clinical Trial Analysis
Figure 2.3 Executive Summary: Patent Analysis
Figure 2.4 Executive Summary: Partnerships and Collaborations
Figure 2.5 Executive Summary: Funding and Investments
Figure 2.6 Executive Summary: Market Forecast
Figure 3.1 Classification of Vaccines
Figure 3.2 Mechanism of Action of Vaccine Adjuvant
Figure 3.3 Advantages of Vaccine Adjuvants
Figure 4.1 Vaccine Adjuvant Developers: Distribution by Year of Establishment
Figure 4.2 Vaccine Adjuvant Developers: Distribution by Company Size
Figure 4.3 Vaccine Adjuvant Developers: Distribution by Location of Headquarters (Region-wise)
Figure 4.4 Vaccine Adjuvant Developers: Distribution by Location of Headquarters (Country-wise)
Figure 4.5 Vaccine Adjuvant Developers: Distribution by Company Size and Location of Headquarters
Figure 4.6 Vaccine Adjuvants: Distribution of Vaccine Adjuvants based on Composition
Figure 4.7 Vaccine Adjuvants: Distribution of Vaccine Adjuvants based on Chemical Structure
Figure 4.8 Vaccine Adjuvants: Distribution of Vaccine Adjuvants based on Function
Figure 4.9 Vaccine Adjuvants: Distribution by Phase of Development
Figure 4.10 Vaccine Adjuvants: Distribution by Type of Product
Figure 4.11 Vaccine Adjuvants: Distribution by Type of Molecular Target
Figure 4.12 Vaccine Adjuvants: Distribution by Route of Administration
Figure 4.13 Vaccine Adjuvants: Distribution by Target Therapeutic Area
Figure 4.14 Vaccine Adjuvants: Distribution by Type of Compatible Vaccines
Figure 4.15 Vaccine Adjuvants: Distribution by Application Area
Figure 4.16 Most Active Players: Distribution by Number of Vaccine Adjuvants Developed
Figure 5.1 Company Competitiveness Analysis: Small Companies
Figure 5.2 Company Competitiveness Analysis: Mid-sized Companies
Figure 5.3 Company Competitiveness Analysis: Large Companies
Figure 9.1 Clinical Trial Analysis: Scope and Methodology
Figure 9.2 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, 2017-2022
Figure 9.3 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, 2017-2022
Figure 9.4 Clinical Trial Analysis: Distribution by Trial Recruitment Status
Figure 9.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, 2017-2022
Figure 9.6 Clinical Trial Analysis: Distribution by Trial Phase
Figure 9.7 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Figure 9.8 Clinical Trial Analysis: Distribution by Target Patient Segment
Figure 9.9 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 9.10 Most Active Industry Players: Distribution by Number of Registered Trials
Figure 9.11 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Figure 9.12 Word Cloud: Key Focus Areas
Figure 9.13 Clinical Trial Analysis: Geographical Distribution by Number of Trials
Figure 9.14 Clinical Trial Analysis: Geographical Distribution by Number of Completed Trials
Figure 9.15 Clinical Trial Analysis: Geographical Distribution by Number of Active Clinical Trials
Figure 9.16 Clinical Trial Analysis: Geographical Distribution by Number of Patients Enrolled
Figure 10.1 Patent Analysis: Distribution by Type of Patent
Figure 10.2 Patent Analysis: Cumulative Distribution by Application Year
Figure 10.3 Patent Analysis: Cumulative Distribution by Publication Year
Figure 10.4 Patent Analysis: Distribution by Location of Patent Jurisdiction (Region-wise)
Figure 10.5 Patent Analysis: Distribution by Location of Patent Jurisdiction (Country-wise)
Figure 10.6 Patent Analysis: Distribution by CPC Symbols
Figure 10.7 Patent Analysis: Emerging Focus Areas
Figure 10.8 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
Figure 10.9 Leading Industry Players: Distribution by Number of Patents
Figure 10.10 Leading Non-Industry Players: Distribution by Number of Patents
Figure 10.11 Leading Patent Assignees: Distribution by Number of Patents
Figure 10.12 Patent Analysis (Top 9 CPC Symbols): Benchmarking by Leading Players
Figure 10.13 Patent Analysis: Distribution by Patent Age
Figure 10.14 Patent Valuation Analysis
Figure 12.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2018-2022
Figure 12.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 12.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 12.4 Partnerships and Collaborations: Distribution by Type of Vaccine Adjuvant
Figure 12.5 Partnerships and Collaborations: Distribution by Type of Product
Figure 12.6 Partnerships and Collaborations: Distribution by Type of Partner
Figure 12.7 Partnerships and Collaborations: Distribution by Year and Type of Partner Company
Figure 12.8 Most Active Players: Distribution by Number of Partnerships
Figure 12.9 Partnerships and Collaborations: Distribution of Intercontinental and Intracontinental Deals
Figure 12.10 Partnerships and Collaborations: Distribution of International and Local Deals
Figure 13.1 Funding and Investments: Cumulative Year-wise Distribution of Funding Instances, 2018-2022
Figure 13.2 Funding and Investments: Cumulative Year-wise Distribution of Amount Invested, 2018-2022 (USD Million)
Figure 13.3 Funding and Investments: Distribution of Funding Instances by Type of Funding
Figure 13.4 Funding and Investments: Distribution of Amount Invested by Type of Funding (USD Million)
Figure 13.5 Funding and Investments: Year-wise Distribution of Amount Invested by Type of Funding (USD Million)
Figure 13.6 Funding and Investments: Distribution of Instances by Type of Investor
Figure 13.7 Funding and Investments: Distribution of Amount Invested by Type of Investor (USD Million)
Figure 13.8 Funding and Investments: Distribution of Instances by Type of Vaccine Adjuvant
Figure 13.9 Most Active Players: Distribution by Number of Funding Instances
Figure 13.10 Most Active Players: Distribution by Amount Invested (USD Million)
Figure 13.11 Most Active Investors: Distribution by Number of Funding Instances
Figure 13.12 Funding and Investments: Distribution of Amount Invested by Geography (Continent-wise) (USD Million)
Figure 13.13 Funding and Investments: Distribution of Amount Invested by Geography (Country-wise) (USD Million)
Figure 14.1 Global Vaccine Adjuvants Market, 2022-2035 (USD Billion)
Figure 14.2 Vaccine Adjuvants Market: Distribution by Type of Vaccine Adjuvant, 2022 and 2035 (USD Billion)
Figure 14.3 Vaccine Adjuvants Market for Aluminum Salts, 2022-2035 (USD Billion)
Figure 14.4 Vaccine Adjuvants Market for Oil-based Emulsions, 2022-2035 (USD Billion)
Figure 14.5 Vaccine Adjuvants Market for Lipids, 2022-2035 (USD Billion)
Figure 14.6 Vaccine Adjuvants Market for Bacterial Compounds, 2022-2035 (USD Billion)
Figure 14.7 Vaccine Adjuvants Market for Nucleic Acids, 2022-2035 (USD Billion)
Figure 14.8 Vaccine Adjuvants Market for Other Adjuvants, 2022-2035 (USD Billion)
Figure 14.9 Vaccine Adjuvants Market: Distribution by Route of Administration, 2022 and 2035 (USD Billion)
Figure 14.10 Vaccine Adjuvants Market for Intramuscular Route, 2022-2035 (USD Billion)
Figure 14.11 Vaccine Adjuvants Market for Subcutaneous Route, 2022-2035 (USD Billion)
Figure 14.12 Vaccine Adjuvants Market for Oral Route, 2022-2035 (USD Billion)
Figure 14.13 Vaccine Adjuvants Market for Intravenous Route, 2022-2035 (USD Billion)
Figure 14.14 Vaccine Adjuvants Market for Other Routes, 2022-2035 (USD Billion)
Figure 14.15 Vaccine Adjuvants Market: Distribution by Target Therapeutic Area, 2022 and 2035 (USD Billion)
Figure 14.16 Vaccine Adjuvants Market for Infectious Diseases, 2022-2035 (USD Billion)
Figure 14.17 Vaccine Adjuvants Market for Oncological Disorders, 2022-2035 (USD Billion)
Figure 14.18 Vaccine Adjuvants Market for Other Disorders, 2022-2035 (USD Billion)
Figure 14.19 Vaccine Adjuvants Market: Distribution by Geography, 2022 and 2035 (USD Billion)
Figure 14.20 Vaccine Adjuvants Market in North America, 2022-2035 (USD Billion)
Figure 14.21 Vaccine Adjuvants Market in Europe, 2022-2035 (USD Billion)
Figure 14.22 Vaccine Adjuvants Market in Asia-Pacific, 2022-2035 (USD Billion)
Figure 14.23 Vaccine Adjuvants Market in MENA, 2022-2035 (USD Billion)
Figure 14.24 Vaccine Adjuvants Market in Latin America, 2022-2035 (USD Billion)
Figure 14.25 Vaccine Adjuvants Market in Rest of the World, 2022-2035 (USD Billion)
Figure 15.1 FDA Approved Adjuvanted Vaccines: Distribution by Year of Approval
Figure 15.2 FDA Approved Adjuvanted Vaccines: Distribution by Number of Adjuvanted Vaccines
Figure 15.3 FDA Approved Adjuvanted Vaccines: Distribution by Type of Vaccine
Figure 15.4 FDA Approved Adjuvanted Vaccines: Distribution by Type of Adjuvant
Figure 15.5 FDA Approved Adjuvanted Vaccines: Distribution by Type of Vaccine and Type of Adjuvant
Figure 15.6 FDA Approved Adjuvanted Vaccines: Distribution by Target Therapeutic Area
Figure 16.1 Concluding Remarks: Overall Market Landscape
Figure 16.2 Concluding Remarks: Clinical Trial Analysis
Figure 16.3 Concluding Remarks: Patent Analysis
Figure 16.4 Concluding Remarks: Partnerships and Collaborations
Figure 16.5 Concluding Remarks: Funding and Investments
Figure 16.6 Concluding Remarks: Market Forecast

List Of Tables

Table 3.1 Vaccines: Examples of Vaccines based on their Type
Table 4.1 List of Vaccine Adjuvant Developers
Table 4.2 Vaccine Adjuvants: Information on Composition, Chemical Structure and Function
Table 4.3 Vaccine Adjuvants: Information on Phase of Development, Type of Product, Molecular Target and Route of Administration
Table 4.4 Vaccine Adjuvants: Information on Target Therapeutic Area, Type of Compatible Vaccine and Application Area
Table 6.1 Leading Vaccine Adjuvant Developers in North America
Table 6.2 Adjuvance Technologies: Company Snapshot
Table 6.3 Adjuvance Technologies: Key Characteristics of Vaccine Adjuvants Offered
Table 6.4 Adjuvance Technologies: Recent Developments and Future Outlook
Table 6.5 Avanti Polar Lipids: Company Snapshot
Table 6.6 Avanti Polar Lipids: Key Characteristics of Vaccine Adjuvants Offered
Table 6.7 Avanti Polar Lipids: Recent Developments and Future Outlook
Table 6.8 Blue Willow Biologics: Company Snapshot
Table 6.9 Blue Willow Biologics: Key Characteristics of Vaccine Adjuvants Offered
Table 6.10 Blue Willow Biologics: Recent Developments and Future Outlook
Table 6.11 Novavax: Company Snapshot
Table 6.12 Novavax: Key Characteristics of Vaccine Adjuvants Offered
Table 6.13 Novavax: Recent Developments and Future Outlook
Table 6.14 Phibro Animal Health: Company Snapshot
Table 6.15 Phibro Animal Health: Key Characteristics of Vaccine Adjuvants Offered
Table 6.16 Phibro Animal Health: Recent Developments and Future Outlook
Table 6.17 Vaxart: Company Snapshot
Table 6.18 Vaxart: Key Characteristics of Vaccine Adjuvants Offered
Table 6.19 Vaxart: Recent Developments and Future Outlook
Table 7.1 Leading Vaccine Adjuvant Developers in Europe
Table 7.2 CureVac: Company Snapshot
Table 7.3 CureVac: Key Characteristics of Vaccine Adjuvants Offered
Table 7.4 CureVac: Recent Developments and Future Outlook
Table 7.5 eTheRNA immunotherapies: Company Snapshot
Table 7.6 eTheRNA immunotherapies: Key Characteristics of Vaccine Adjuvants Offered
Table 7.7 eTheRNA immunotherapies: Recent Developments and Future Outlook
Table 7.8 GSK: Company Snapshot
Table 7.9 GSK: Key Characteristics of Vaccine Adjuvants Offered
Table 7.10 GSK: Recent Developments and Future Outlook
Table 8.1 Leading Vaccine Adjuvant Developers in Asia-Pacific
Table 8.2 Advagene Biopharma: Company Snapshot
Table 8.3 Advagene Biopharma: Key Characteristics of Vaccine Adjuvants Offered
Table 8.4 OBI Pharma: Company Snapshot
Table 8.5 OBI Pharma: Key Characteristics of Vaccine Adjuvants Offered
Table 10.1 Patent Analysis: Prominent CPC Symbols
Table 10.2 Patent Analysis: Most Popular CPC Symbols
Table 10.3 Patent Analysis: List of Top CPC Symbols
Table 10.4 Patent Analysis: Summary of Benchmarking Analysis
Table 10.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 10.6 Patent Portfolio: List of Leading Patents (in terms of Highest Relative Valuation)
Table 10.7 Patent Portfolio: List of Leading Patents (in terms of Number of Citations)
Table 11.1 Most Likely Partners in North America
Table 11.2 Likely Partners in North America
Table 11.3 Less Likely Partners in North America
Table 11.4 Most Likely Partners in Europe
Table 11.5 Likely Partners in Europe
Table 11.6 Less Likely Partners in Europe
Table 11.7 Most Likely Partners in Asia Pacific
Table 11.8 Likely Partners Asia Pacific
Table 11.9 Less Likely Partners in Asia Pacific
Table 12.1 Vaccine Adjuvants: List of Partnerships and Collaborations, 2018-2022
Table 13.1 Vaccine Adjuvants: List of Funding and Investments, 2018-2022,
Table 13.2 Vaccine Adjuvants: Summary of Investments
Table 15.1 List of FDA Approved Vaccines
Table 17.1 Adjuvantis: Company Snapshot
Table 17.2 Kupando; Company Snapshot
Table 17.3 Pacific GeneTech: Company Snapshot
Table 18.1 Vaccine Adjuvant Developers: Distribution by Year of Establishment
Table 18.2 Vaccine Adjuvant Developers: Distribution by Company Size
Table 18.3 Vaccine Adjuvant Developers: Distribution by Location of Headquarters (Region-wise)
Table 18.4 Vaccine Adjuvant Developers: Distribution by Location of Headquarters (Country-wise)
Table 18.5 Vaccine Adjuvant Developers: Distribution by Company Size and Location of Headquarters
Table 18.6 Vaccine Adjuvants: Distribution of Vaccine Adjuvants based on Composition
Table 18.7 Vaccine Adjuvants: Distribution of Vaccine Adjuvants based on Chemical Structure
Table 18.8 Vaccine Adjuvants: Distribution of Vaccine Adjuvants based on Function
Table 18.9 Vaccine Adjuvants: Distribution by Phase of Development
Table 18.10 Vaccine Adjuvants: Distribution by Type of Product
Table 18.11 Vaccine Adjuvants: Distribution by Type of Molecular Targets
Table 18.12 Vaccine Adjuvants: Distribution by Route of Administration
Table 18.13 Vaccine Adjuvants: Distribution by Target Therapeutic Area
Table 18.14 Vaccine Adjuvants: Distribution by Type of Compatible Vaccines
Table 18.15 Vaccine Adjuvants: Distribution by Application Area
Table 18.16 Most Active Players: Distribution by Number of Vaccine Adjuvants Developed
Table 18.17 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, 2017-2022
Table 18.18 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, 2017-2022
Table 18.19 Clinical Trial Analysis: Distribution by Trial Recruitment Status
Table 18.20 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, 2017-2022
Table 18.21 Clinical Trial Analysis: Distribution by Trial Phase
Table 18.22 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Table 18.23 Clinical Trial Analysis: Distribution by Target Patient Segment
Table 18.24 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 18.25 Most Active Industry Players: Distribution by Number of Registered Trials
Table 18.26 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Table 18.27 Clinical Trial Analysis: Geographical Distribution by Number of Clinical Trials
Table 18.28 Clinical Trial Analysis: Geographical Distribution by Number of Completed Clinical Trials
Table 18.29 Clinical Trial Analysis: Geographical Distribution by Number of Active Clinical Trials
Table 18.30 Clinical Trial Analysis: Geographical Distribution by Number of Patients Enrolled
Table 18.31 Patent Analysis: Distribution by Type of Patent
Table 18.32 Patent Analysis: Cumulative Distribution by Application Year
Table 18.33 Patent Analysis: Cumulative Distribution by Publication Year
Table 18.34 Patent Analysis: Distribution by Location of Patent Jurisdiction (Region-wise)
Table 18.35 Patent Analysis: Distribution by Location of Patent Jurisdiction (Country-wise)
Table 18.36 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
Table 18.37 Leading Industry Players: Distribution by Number of Patents
Table 18.38 Leading Non-Industry Players: Distribution by Number of Patents
Table 18.39 Leading Patent Assignees: Distribution by Number of Patents
Table 18.40 Patent Analysis: Distribution by Patent Age
Table 18.41 Patent Valuation Analysis
Table 18.42 Partnerships and Collaborations: Cumulative Year-wise Trend, 2018-2022
Table 18.43 Partnerships and Collaborations: Distribution by Type of Partnership
Table 18.44 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 18.45 Partnerships and Collaborations: Distribution by Type of Vaccine Adjuvant
Table 18.46 Partnerships and Collaborations: Distribution by Type of Product
Table 18.47 Partnerships and Collaborations: Distribution by Type of Partner Company
Table 18.48 Partnerships and Collaborations: Distribution by Year and Type of Partner Company
Table 18.49 Most Active Players: Distribution by Number of Partnerships
Table 18.50 Partnerships and Collaborations: Distribution of Intercontinental and Intracontinental Deals
Table 18.51 Partnerships and Collaborations: Distribution of International and Local Deals
Table 18.52 Funding and Investments: Cumulative Year-wise Distribution of Funding Instances, 2018-2022
Table 18.53 Funding and Investments: Cumulative Year-wise Distribution of Amount Invested, 2018-2022 (USD Million)
Table 18.54 Funding and Investments: Distribution of Funding Instances by Type of Funding
Table 18.55 Funding and Investments: Distribution of Amount Invested by Type of Funding (USD Million)
Table 18.56 Funding and Investments: Year-wise Distribution of Amount Invested by Type of Funding (USD Million)
Table 18.57 Funding and Investments: Distribution of Number of Funding Instances by Type of Investor
Table 18.58 Funding and Investments: Distribution of Amount Invested by Type of Investor (USD Million)
Table 18.59 Funding and Investments: Distribution of Number of Funding Instances by Type of Vaccine Adjuvant
Table 18.60 Most Active Players: Distribution by Number of Funding Instances
Table 18.61 Most Active Players: Distribution by Amount Invested (USD Million)
Table 18.62 Most Active Investors: Distribution by Number of Funding Instances
Table 18.63 Funding and Investments: Distribution of Amount Invested by Geography (Continent-wise) (USD Million)
Table 18.64 Funding and Investments: Distribution of Amount Invested by Geography (Country-wise) (USD Million)
Table 18.65 Global Vaccine Adjuvants Market, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 18.66 Vaccine Adjuvants Market: Distribution by Type of Vaccine Adjuvants, 2022 and 2035 (USD Billion)
Table 18.67 Vaccine Adjuvants Market for Aluminum Salts, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 18.68 Vaccine Adjuvants Market for Oil-based Emulsions, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 18.69 Vaccine Adjuvants Market for Lipids, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 18.70 Vaccine Adjuvants Market for Bacterial Compounds, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 18.71 Vaccine Adjuvants Market for Nucleic Acids, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 18.72 Vaccine Adjuvants Market for Other Adjuvants, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 18.73 Vaccine Adjuvants Market: Distribution by Route of Administration, 2022 and 2035 (USD Billion)
Table 18.74 Vaccine Adjuvants Market for Intramuscular Route, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 18.75 Vaccine Adjuvants Market for Subcutaneous Route, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 18.76 Vaccine Adjuvants Market for Oral Route, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 18.77 Vaccine Adjuvants Market for Intravenous Route, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 18.78 Vaccine Adjuvants Market for Other Routes, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 18.79 Vaccine Adjuvants Market: Distribution by Target Therapeutic Area, , 2022 and 2035 (USD Billion)
Table 18.80 Vaccine Adjuvants Market for Infectious Diseases, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 18.81 Vaccine Adjuvants Market for Oncological Disorders, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 18.82 Vaccine Adjuvants Market for Other Disorders, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 18.83 Vaccine Adjuvants Market: Distribution by Geography, 2022 and 2035 (USD Billion)
Table 18.84 Vaccine Adjuvants Market in the North America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 18.85 Vaccine Adjuvants Market in the Europe, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 18.86 Vaccine Adjuvants Market in the Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 18.87 Vaccine Adjuvants Market in the MENA, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 18.88 Vaccine Adjuvants Market in the Latin America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 18.89 Vaccine Adjuvants Market in the Rest of the World, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 18.90 FDA Approved Adjuvanted Vaccines: Distribution by Year of Approval
Table 18.91 FDA Approved Adjuvanted Vaccines: Distribution by Number of Adjuvanted Vaccine
Table 18.92 FDA Approved Adjuvanted Vaccines: Distribution by Type of Vaccine
Table 18.93 FDA Approved Adjuvanted Vaccines: Distribution by Type of Adjuvant
Table 18.94 FDA Approved Adjuvanted Vaccines: Distribution by Type of Vaccine and Type of Adjuvant
Table 18.95 FDA Approved Adjuvanted Vaccines: Distribution by Target Therapeutic Area

List Of Companies

The following companies and organizations have been mentioned in the report:

  1. 3M
  2. 4D Pharma
  3. Adit Ventures
  4. Adjuvance Technologies
  5. Adjuvatis
  6. Advaccine
  7. Advagene Biopharma
  8. Afrigen Biologics
  9. AGC Biologics
  10. Agenus
  11. AgriLabs
  12. Albertsons Companies
  13. Allergy Therapeutics
  14. Alliance Foundation Trials
  15. AlphaVax
  16. Amgen
  17. Amyris
  18. APC
  19. Aston Sci
  20. AuraVax Therapeutics
  21. Avanti Polar Lipids
  22. Avenue Capital
  23. Aviragen Therapeutics
  24. Bavarian Nordic
  25. Bharat Biotech
  26. Bill & Melinda Gates Foundation
  27. Biological E
  28. BioNTech
  29. Biosonda
  30. Biovac
  31. BlueWillow Biologics
  32. Boehringer Ingelheim
  33. Breast International Group
  34. Brenntag Biosector
  35. Bristol Myers Squibb
  36. CaPtivate Pharmaceuticals
  37. Catalent Biologics
  38. Celgene
  39. CEPI
  40. CinnaGen
  41. Cleveland BioLabs
  42. Clover Biopharmaceuticals
  43. Coalition for Epidemic Preparedness Innovations
  44. Coley Pharmaceutical
  45. Commonwealth of Australia
  46. CordenPharma
  47. Core Research Grant (CRG)
  48. Croda
  49. CSL
  50. CureVac
  51. CyTuVax
  52. Dana-Farber Cancer Institute
  53. Duke University
  54. Dynavax Technologies
  55. Eisai
  56. Emergent BioSolutions
  57. eTheRNA immunotherapies
  58. European Commission
  59. EuBiologics
  60. Eurocine Vaccines
  61. European Commission
  62. European Investment Bank
  63. Foris Ventures
  64. FUJIFILM Diosynth Biotechnologies
  65. Gavi
  66. Genocea Biosciences
  67. Georgia Institute of Technology
  68. German Federal Ministry of Education and Research
  69. German Federal Government (Kreditanstalt für Wiederaufbau)
  70. GI Innovation
  71. Ginkgo Bioworks
  72. Global Emerging Markets (GEM)
  73. Government of Canada
  74. Government of New Zealand
  75. Government of Switzerland
  76. Government of UK
  77. GSK
  78. Harvard College
  79. Hawaii Biotech
  80. Hayashibara
  81. Heat Biologics
  82. Herlev Hospital
  83. Huvepharma
  84. iBio
  85. Icahn School of Medicine
  86. Immatics Biotechnologies
  87. Immune Response BioPharma
  88. ImmuneRegen BioSciences
  89. ImmunoPrecise Antibodies
  90. Infectious Disease Research Institute (IDRI)
  91. Innovate UK
  92. International Vaccine Institute (IVI)
  93. Invest-NL
  94. ISA Pharmaceuticals
  95. Immune System Regulation (ISR)
  96. Ministry of Health Israel
  97. Jiangsu Recbio Technology
  98. Kemin Industries
  99. Kineta
  100. Kupando
  101. La Jolla Institute
  102. Line Moon Ventures
  103. LiteVax
  104. Mabion
  105. Massachusetts General Hospital
  106. Massachusetts Institute of Technology
  107. Matrix Partners
  108. Medicago
  109. Medigen Vaccine Biologics
  110. Medytox
  111. Memorial Sloan Kettering Cancer Center
  112. Merck
  113. Molecular Express
  114. Morningside Venture Investments
  115. N4 Pharma
  116. Nanometrics
  117. National Institute of Allergy and Infectious Diseases (NIAID)
  118. National Institutes of Health
  119. NeoImmuneTech
  120. NIH Small Business Innovation Research (SBIR)
  121. North Coast Technology Investors
  122. Novartis
  123. Novavax
  124. OBI Pharma
  125. Oncovir
  126. Oragenics
  127. OX2 Therapeutics
  128. OZ Biosciences
  129. Pacific GeneTech
  130. Phibro Animal Health
  131. Praha Vaccines
  132. Qatar Investment Authority
  133. RA Capital
  134. Regeneron
  135. Roche
  136. Roquette
  137. Sam’s Club
  138. Sanofi
  139. Sanofi Pasteur
  140. SapVax
  141. Scarab Genomics
  142. Seppic
  143. Seqirus
  144. Serum Institute of India
  145. Shenzhen Rhegen Biotechnology
  146. Sinocelltech
  147. Sinovac Biotech
  148. STAR Capital
  149. Statens Serum Institut
  150. Statera Biopharma
  151. Sumitomo Dainippon Pharma
  152. Takeda Pharmaceutical
  153. US Government
  154. TRANSVAC2
  155. Ubix Therapeutics
  156. University of California
  157. University of Houston
  158. University of Michigan
  159. University of Pennsylvania
  160. University of Queensland
  161. University of Saskatchewan (Usask)
  162. University of Texas
  163. USHealth
  164. Vaccine Formulation Institute (VFI)
  165. Valneva
  166. Vaxart
  167. Vaxine
  168. Vir Biotechnology
  169. ViroVax
  170. Viscogel
  171. Wisconsin Alumni Research Foundation (WARF)
  172. Zoetis

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 8) n a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com